Literature DB >> 28984630

Perioperative Management of the Adult Patient on Venovenous Extracorporeal Membrane Oxygenation Requiring Noncardiac Surgery.

Michael A Fierro1, Mani A Daneshmand, Raquel R Bartz.   

Abstract

The use of venovenous extracorporeal membrane oxygenation is increasing worldwide. These patients often require noncardiac surgery. In the perioperative period, preoperative assessment, patient transport, choice of anesthetic type, drug dosing, patient monitoring, and intraoperative and postoperative management of common patient problems will be impacted. Furthermore, common monitoring techniques will have unique limitations. Importantly, patients on venovenous extracorporeal membrane oxygenation remain subject to hypoxemia, hypercarbia, and acidemia in the perioperative setting despite extracorporeal support. Treatments of these conditions often require both manipulation of extracorporeal membrane oxygenation settings and physiologic interventions. Perioperative management of anticoagulation, as well as thresholds to transfuse blood products, remain highly controversial and must take into account the specific procedure, extracorporeal membrane oxygenation circuit function, and patient comorbidities. We will review the physiologic management of the patient requiring surgery while on venovenous extracorporeal membrane oxygenation.

Entities:  

Mesh:

Year:  2018        PMID: 28984630     DOI: 10.1097/ALN.0000000000001887

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  2 in total

1.  Simple equations to predict the effects of veno-venous ECMO in decompensated Eisenmenger syndrome.

Authors:  Jean Bonnemain; Denise Auberson; Tobias Rutz; Patrick Yerly; John-David Aubert; Aurélien Roumy; Olivier Pantet; Marco Rusca; Lucas Liaudet; Lise Piquilloud
Journal:  ESC Heart Fail       Date:  2021-02-25

2.  Relationship between 30 Days Mortality and Incidence of Intraoperative Cardiac Arrest According to the Timing of ECMO.

Authors:  Taehwa Kim; Seungeun Lee; Sungkwang Lee
Journal:  J Clin Med       Date:  2021-05-05       Impact factor: 4.241

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.